Dazodalibep clinical trials
Dazodalibep is named as an intervention in 2 current clinical trials in our UK, USA, Germany, France, Spain, Italy, Belgium, Poland, Portugal, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia and Israel registers. 1 is recruiting patients now. All registered phases are Phase 3. The lead sponsor is Amgen. The most-studied condition is Sjögren's Syndrome (SS).
How Dazodalibep works
All drug targets →- CD40 ligand antagonist AntagonistTarget: CD40LG CD40 ligandChEMBL only
- Sjogren syndromePhase 3
- Lupus nephritisPhase 2
- Rheumatoid arthritisPhase 2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL4594331, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 13453, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Dazodalibep
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Dazodalibep
2 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
NCT06747949 · Sjögren's Syndrome
|
Phase 3 | Recruiting | Amgen | UK, USA, Germany, France, Spain, Italy, Belgium, Poland, Portugal, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel |
|
A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State
NCT06245408 · Sjögren's Syndrome (SS)
|
Phase 3 | Active, closed | Amgen | UK, USA, Germany, France, Spain, Italy, Belgium, Poland, Portugal, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Dazodalibep
2 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Amgen | 2 |
By country register
A trial with sites in more than one country appears in each of those registers.
Questions about Dazodalibep trials
How many clinical trials are testing Dazodalibep?
2 current trials in our UK, USA, Germany, France, Spain, Italy, Belgium, Poland, Portugal, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia and Israel registers name Dazodalibep (also registered as VIB 4920) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Dazodalibep trials recruiting patients?
Yes. 1 of the 2 trials is recruiting: 1 with sites in UK, 1 with sites in USA, 1 with sites in Germany, 1 with sites in France, 1 with sites in Spain, 1 with sites in Italy, 1 with sites in Belgium, 1 with sites in Poland, 1 with sites in Portugal, 1 with sites in Canada, 1 with sites in Brazil, 1 with sites in Mexico, 1 with sites in Japan, 1 with sites in South Korea, 1 with sites in Taiwan, 1 with sites in Australia and 1 with sites in Israel. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Dazodalibep clinical trials?
The lead sponsor is Amgen. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Dazodalibep works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Dazodalibep works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Dazodalibep (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.